Evaluation of the effectiveness of serelaxin in the treatment of patients with acute decompensation of heart failure: Five-year follow-up

Aim. To evaluate the effectiveness of serelaxin with subsequent quadritherapy in the treatment of patients with acute decompensation of heart failure in the long term outcomes.

Material and Methods. A five-year observational, comparative, longitudinal study was conducted with the participation of 34 patients with heart failure. Standard laboratory and instrumental methods of examination were performed, including the determination of the level of Nt-proBNP, electrocardiography, echocardiography. The quality of life was assessed on the basis of the SF-36 questionnaire, the state of health using a visual analog scale (VAS), a survival forecast was made using the MAGGIC scale and the Seattle Heart Failure Model calculator. The assessment of adherence to treatment was carried out using the questionnaire “COP-25”.

Results and Discussion. With serelaxin therapy at the 14th day, there was a significant decrease (p ˂ 0,05) of Nt-proBNP level, pulmonary artery pressure, as well as an increase of left ventricular (LV) ejection fraction (EF) by an average of 5%, which coincided with the leveling of manifestations of heart failure (HF) decompensation and improvement of clinical and instrumental parameters. There was a statistically significant (p ˂ 0,05) improvement in the quality of life based on the patient’s subjective assessment. Stable positive dynamics was recorded on the basis of the SF-36 questionnaire for all health indicators, not only physical, but also social and mental. Subsequent quadrotherapy reduced the mortality rate of patients in the study cohort of patients, as well as increased adherence to treatment.

Conclusion. The use of serelaxin does not lead to a decrease in cardiovascular mortality, however, it reduces the number of hospitalizations due to acute decompensation of heart failure. The subsequent quadrotherapy leads to an increase in the quality of life, physical, social activity and adherence to the treatment. Reverse remodeling of the left heart chambers and an increase in EF LV is characterized by a decrease of the functional class of CHF, which indicates the influence of this therapy on the key pathogenetic mechanisms of the disease.

1. Gheorghiade M., Vaduganathan M., Fonarow G.C., Bonow R.O. Rehospitalization for heart failure: problems and perspectives. J. Am. Coll. Cardiol. 2013;61(4):391–403. DOI: 10.1016/j.jacc.2012.09.038.

2. Teerlink J.R., Cotter G., Davison B.A., Felker G.M., Filippatos G., Greenberg B.H. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39. DOI: 10.1016/S0140-6736(12)61855-8.

3. McMurray J.J.V., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014;371:993–1004. DOI: 10.1056/NEJMoa1409077.

4. Fitchett D., Butler J., van de Borne P., Zinman B., Lachin J.M., Wanner C. et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur. Heart J. 2017. DOI: 10.1093/eurheartj/ehx511.

5. Wright E.M., Loo D.D., Hirayama B.A. Biology of human sodium glucose transporters. Physiol. Rev. 2011;91(2):733–794. DOI: 10.1152/physrev.00055.2009.

6. Ponikowski P., Mitrovic V., Ruda M., Fernandez A., Voors A.A., Vishnevsky A. et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur. Heart J. 2014;35(7):431–441 DOI: 10.1093/eurheartj/eht459.

7. Munzel T., Steven S., Daiber A. Organic nitrates: Гpdate on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. Vascul. Pharmacol. 2014;63(3):105–113. DOI: 10.1016/j.vph.2014.09.002.

8. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: What has changed over 20 years of follow-up? Results of the EPOCHA-CHF study. Kardiologiia. 2021;61(4):4–14. (In Russ.). DOI: 10.18087/cardio.2021.4.n1628.

9. Vinogradova N.G., Polyakov D.S., Fomin I.V. Analysis of mortality in patients with heart failure after decompensation during longterm follow-up in specialized medical care and in real clinical practice. Kardiologiia. 2020;60(4):91–100. (In Russ.). DOI: 10.18087/cardio.2020.4.n1014.

10. Polyakov D.S., Fomin I.V., Vaisberg A.R. Evaluation of long-term predictors in patients with acute decompensated heart failure depending on age: The results of the EPOCHA-D-CHF study. Clinical Gerontology. 2019;25(3–4):39–47. (In Russ.). DOI: 10.26347/1607-249920190304039-047.

11. Nikolaev N.A. Guidelines for Clinical Research in Internal Medicine (scientific monograph). Moscow; 2015:74. (In Russ.).

12. Samuel C.S., Hewitson T.D., Unemori E.N., Tang M.L.-K. Drugs of the future: The hormone relaxin. Cell. Mol. Life Sci. 2007;64(12):1539–1557. DOI: 10.1007/s00018-007-6543-y.